- Home
- GEF vs ACAD Comparison
GEF vs ACAD Comparison
Compare GEF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEF
- ACAD
- Stock Information
- Founded
- GEF 1877
- ACAD 1993
- Country
- GEF United States
- ACAD United States
- Employees
- GEF N/A
- ACAD N/A
- Industry
- GEF
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- GEF
- ACAD Health Care
- Exchange
- GEF Nasdaq
- ACAD Nasdaq
- Market Cap
- GEF 3.2B
- ACAD 2.8B
- IPO Year
- GEF N/A
- ACAD 2004
- Fundamental
- Price
- GEF $54.97
- ACAD $16.61
- Analyst Decision
- GEF Buy
- ACAD Buy
- Analyst Count
- GEF 7
- ACAD 17
- Target Price
- GEF $75.67
- ACAD $24.00
- AVG Volume (30 Days)
- GEF 159.8K
- ACAD 1.5M
- Earning Date
- GEF 02-26-2025
- ACAD 05-07-2025
- Dividend Yield
- GEF 3.93%
- ACAD N/A
- EPS Growth
- GEF N/A
- ACAD N/A
- EPS
- GEF 4.43
- ACAD 1.36
- Revenue
- GEF $5,508,100,000.00
- ACAD $957,797,000.00
- Revenue This Year
- GEF N/A
- ACAD $13.07
- Revenue Next Year
- GEF $12.04
- ACAD $9.97
- P/E Ratio
- GEF $12.40
- ACAD $12.28
- Revenue Growth
- GEF 6.88
- ACAD 31.85
- 52 Week Low
- GEF $53.43
- ACAD $14.15
- 52 Week High
- GEF $73.16
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- GEF 41.57
- ACAD 36.91
- Support Level
- GEF $54.20
- ACAD $16.86
- Resistance Level
- GEF $56.22
- ACAD $17.31
- Average True Range (ATR)
- GEF 1.26
- ACAD 0.51
- MACD
- GEF 0.13
- ACAD -0.00
- Stochastic Oscillator
- GEF 45.70
- ACAD 23.24
About GEF Greif Inc.
Greif Inc is a producer of industrial packaging products and services with manufacturing facilities located in many countries. It offers a comprehensive line of rigid industrial packaging products, such as steel, fiber, and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and remanufactured and reconditioned industrial containers, and services, such as container life cycle management, blending, filling, logistics, warehousing, and other packaging services. The company operates in three reportable business segments including Global Industrial Packaging, Paper Packaging and Services, and Land Management. It operates in USA, Europe, Middle East, Africa and Asia and Other Americas.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.